Pneumococcal vaccine - Antigenics

Drug Profile

Pneumococcal vaccine - Antigenics

Alternative Names: Quilimmune-P

Latest Information Update: 28 Aug 2006

Price : $50

At a glance

  • Originator Antigenics
  • Class Pneumococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Pneumococcal infections

Most Recent Events

  • 28 Aug 2006 Discontinued - Phase-I for Pneumococcal infections in USA (unspecified route)
  • 09 May 2002 Phase-I clinical trials in Pneumococcal infections in USA (unspecified route)
  • 09 May 2002 Data from a phase I study have been added to the Bacterial Infections immunogenicity section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top